1000578-10-8

Basic information

• Product Name: METHYL 4-OXO-3,4-DIHYDROQUINAZOLINE-8-CARBOXYLATE
• Synonyms: METHYL 3,4-DIHYDRO-4-OXOQUINAZOLINE-8-CARBOXYLATE;METHYL 4-OXO-3,4-DIHYDROQUINAZOLINE-8-CARBOXYLATE;3,4-Dihydro-4-oxo-8-quinazolinecarboxylic acid methyl ester;4-dihydroquinazoline-8-carboxylate;Methyl 4-oxo-3;METHYL 4-OXO-3,4-DIHYDROQUINAZOLINE-8-CARBOXYLATE(WXG01643)
• CAS NO: 1000578-10-8
• Molecular Formula: C₁₀H₈N₂O₃
• Molecular Weight: 204.18212
• Mol File: 1000578-10-8.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 450.9 °C at 760 mmHg
• Flash Point: 226.5 °C
• Appearance: White crystalline powder
• Density: 1.39
• PKA: 0.43±0.20(Predicted)
• CAS DataBase Reference: METHYL 4-OXO-3,4-DIHYDROQUINAZOLINE-8-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-OXO-3,4-DIHYDROQUINAZOLINE-8-CARBOXYLATE(1000578-10-8)
• EPA Substance Registry System: METHYL 4-OXO-3,4-DIHYDROQUINAZOLINE-8-CARBOXYLATE(1000578-10-8)

Safety Data

• Hazardous Substances Data: 1000578-10-8(Hazardous Substances Data)

Usage

General Description

Methyl 4-oxo-3,4-dihydroquinazoline-8-carboxylate is a chemical compound with the molecular formula C11H10N2O3. It is an ester derivative of 4-oxo-3,4-dihydroquinazoline-8-carboxylic acid, which is a heterocyclic compound. methyl 4-oxo-3,4-dihydroquinazoline-8-carboxylate has been studied for its potential pharmaceutical applications, and it may have uses in the development of new drugs or as a precursor in organic synthesis. Its structure suggests possible pharmacological activity, though further research is needed to fully understand its potential effects and applications. methyl 4-oxo-3,4-dihydroquinazoline-8-carboxylate is of interest to both chemists and pharmacologists as a potential building block in drug development.

Upstream product

• 39622-79-2 2-aminoisophthalic acid 

Downstream Products

• 1379545-91-1 4-[(S)-2-azetidin-1-yl-1-(3-fluorophenyl)-ethylamino]-quinazoline-8-carboxamide 
• 1240479-87-1 4-[(S)-1-(3-fluoro-phenyl)-2-methylamino-ethylamino]-quinazoline-8-carboxamide 
• 1240474-33-2 4-[1-(3-fluoro-phenyl)-2-methylamino-ethylamino]-quinazoline-8-carboxamide 
• 1240472-83-6 4-((S)-2-methoxy-1-phenyl-ethylamino)-quinazoline-8-carboxamide 
• 1240474-61-6 4-((S)-2-dimethylamino-1-phenyl-ethylamino)-quinazoline-8-carboxamide 
• 1240476-05-4 4-((S)-2-cyclopropylamino-1-phenyl-ethylamino)-quinazoline-8-carboxamide 

Relevant articles and documents

Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers

Herein, we report the discovery of a novel class of quinazoline carboxamides as dual p70S6k/Akt inhibitors for the treatment of tumors driven by alterations to the PI3K/Akt/mTOR (PAM) pathway. Through the screening of in-house proprietary kinase library, 4-benzylamino-quinazoline-8-carboxylic acid amide 1 stood out, with sub-micromolar p70S6k biochemical activity, as the starting point for a structurally enabled p70S6K/Akt dual inhibitor program that led to the discovery of M2698, a dual p70S6k/Akt inhibitor. M2698 is kinase selective, possesses favorable physical, chemical, and DMPK profiles, is orally available and well tolerated, and displayed tumor control in multiple in vivo studies of PAM pathway-driven tumors.